Resumo:
En
|
Texto:
En
|
PDF:
En
Abstract Objective: This study aimed to evaluate the diagnostic utility, disease activity, and phenotypic association of serum anti-Saccharomyces cerevisiae antibody (ASCA), perinuclear anti-neutrophil cytoplasmic antibody (pANCA), PR3-ANCA, and MPO-ANCA in pediatric patients with inflammatory bowel disease (IBD). Methods: Pediatric patients diagnosed with IBD were recruited and classified as Crohn’s disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U) through full investigation. The Paris classification was used to evaluate disease phenotypes of pediatric CD and UC. Results: In all, 229 pediatric patients with IBD (CD 147, UC 53, IBD-U 29) were included. The ASCA IgG seropositivity significantly differed among the three groups (CD 75.4%, UC 17.5%, and IBD-U 60.0%; p < 0.001). PR3-ANCA positive rates were the highest in UC (24.0%), followed by IBD-U (17.6%), and none in CD (p = 0.002); pANCA-positive rates were higher in IBD-U (33.6%), followed by UC (28.0%) than in CD (1.4%) (p < 0.001). Regarding disease phenotype, perianal disease revealed higher serum ASCA IgG titers (median 36.7 U/mL in P1 vs. 25.2 U/mL in P0, p = 0.019). Serum ASCA IgG and IgA cutoff values to distinguish CD were 32.7 (U/mL) and 11.9 (U/mL), respectively, with a specificity of 80.0%. Conclusion: Serological biomarkers of ASCA IgG and IgA were effective for differentiating CD in pediatric IBD patients, and serum pANCA and PR3-ANCA, but not MPO-ANCA, were effective in distinguishing UC and IBD-U. Furthermore, measuring serological titers of ASCA IgG and IgA may help differentiate CD and evaluate the disease activity and phenotype of pediatric IBD in practice. Objective utility antiSaccharomyces anti Saccharomyces ASCA, , (ASCA) antineutrophil neutrophil pANCA, (pANCA) PR3ANCA, PR3ANCA PRANCA PR3 ANCA, ANCA PR MPOANCA MPO IBD. . (IBD) Methods Crohns Crohn s CD, (CD) UC, (UC) IBDunclassified unclassified IBDU U (IBD-U investigation Results all 22 147 53 29 included 754 75 4 75.4% 175 17 5 17.5% 60.0% 600 60 0 0.001. 0001 0.001 001 0.001) 24.0%, 240 24.0% 24 (24.0%) 17.6%, 176 17.6% 6 (17.6%) 0.002 0002 002 0.002) pANCApositive 33.6%, 336 33.6% 33 (33.6%) 28.0% 280 28 (28.0% 1.4% 14 1 (1.4% median 367 36 7 36. UmL mL P vs 252 25 2 25. P0 0.019. 0019 0.019 019 0.019) 327 32 32. (U/mL 119 11 9 11. U/mL, respectively 800 80 80.0% Conclusion MPOANCA, IBDU. U. Furthermore practice (ASCA (pANCA (IBD (UC 75.4 17.5 60.0 000 0.00 00 24.0 (24.0% 17.6 (17.6% 33.6 3 (33.6% 28.0 (28.0 1.4 (1.4 0.01 01 8 80.0 75. 17. 60. 0.0 24. (24.0 (17.6 33. (33.6 28. (28. 1. (1. 80. 0. (24. (17. (33. (28 (1 (24 (17 (33 (2 ( (3